Acral Melanoma and a Different Genome: Testing for KIT Before Committing to Immunotherapy
A single patient whose melanoma looks like ordinary metastatic disease on a scan but carries a genuinely different genomic profile than the cutaneous melanoma most trial data describes. The disagreement is about whether that difference is large enough to justify waiting on a test before starting treatment.
L.P., a 67-year-old woman, spent thirty-one years sorting mail on foot before retiring, and had been treating a dark, slowly enlarging patch on the sole of her right foot as a stubborn callus for well over a year, using drugstore keratolytic pads that never quite worked the way the label promised. A podiatry visit finally biopsied it: acral lentiginous melanoma, and staging CT found three pulmonary nodules consistent with metastatic disease. She has no other significant medical history and reports feeling entirely well aside from mild, intermittent shortness of breath she'd attributed to being out of shape.
Acral melanoma is a genuinely different disease at the molecular level from the sun-exposed cutaneous melanoma most immunotherapy trial data describes, and that difference bears directly on what to do next. It carries a far lower tumor mutational burden — driven by chronic mechanical trauma rather than UV-signature mutations — which tracks with meaningfully lower response rates to anti-PD-1 therapy, roughly 15 to 20 percent in acral and mucosal subtypes against roughly 40 percent in typical cutaneous melanoma. What acral melanoma has instead, in a real minority of cases, is a KIT alteration: activating mutations or amplifications in the same receptor tyrosine kinase gene targeted by imatinib in gastrointestinal stromal tumors, present in roughly one in five to one in six acral and mucosal melanomas but essentially absent from UV-driven cutaneous disease. The shared alteration frequency is where that acral-and-mucosal pairing stops being safe, though. In Hodi's phase II trial of imatinib in KIT-altered melanoma, every response occurred in a mucosal primary — 41 percent of those patients, against none of the acral or chronically sun-damaged ones — and responses were confined to tumors carrying a KIT mutation rather than an amplification alone. Guo's series found the same ordering, with acral response rates running below mucosal. Her primary is acral, which places her on the thin side of the only line those trials actually drew.
Genomic testing for KIT status takes two to three weeks to return, and her three pulmonary nodules, while not currently causing symptoms severe enough to demand same-day treatment, are large enough that a delay isn't free. Her mild dyspnea, read against three visible nodules rather than a diffuse process, is more likely mechanical crowding than anything approaching respiratory compromise — reassuring in itself, but not a reason to treat the timeline as unlimited. So what the team has to settle is not really whether her KIT status matters, but whether a result whose own supporting response data come from a different primary site is worth two to three weeks of untreated pulmonary disease to obtain first.
Whether to wait on a test result before choosing a first drug
Acral melanoma isn't the same disease at the genomic level as the cutaneous melanoma most of our immunotherapy data comes from. Roughly one in five to one in six carries a KIT alteration, essentially absent from UV-driven disease. I'll be straight about the limits of the imatinib data: in Hodi's trial every response was in a mucosal primary and none in an acral one, and Guo's series put acral below mucosal too. Those are small single-arm studies with a handful of acral patients each, and her expected response to anti-PD-1 in this subtype is only 15 to 20 percent. I'd still want her KIT status before choosing, not after.
I don't disagree with the biology. I disagree with treating a 15 to 20 percent response rate as too low to bother with while we wait two to three weeks for a test result in a patient with new pulmonary metastases. Even a minority of immunotherapy responders in this subtype get genuinely durable disease control, and that durability gap over KIT-inhibitor responses — which tend to be shorter and partial — is real.
And you've just named the larger problem yourself: the response data you'd be acting on come from mucosal primaries. Hers is acral. Four or five times out of six the panel returns negative anyway — and in the fraction where it's positive, the trial evidence that imatinib does anything for an acral primary specifically is close to absent. That's two to three weeks of untreated pulmonary disease spent on a result that may not change what we do either way.
I think this is being framed as a choice between two drugs when it's actually a question of what order they go in. Nothing about starting pembrolizumab today closes the door on imatinib later if the KIT result comes back positive and she needs a next option — the two classes aren't competing for the same treatment slot, they're sequential options.
Start pembrolizumab now given her disease burden. Send the KIT panel in parallel, not instead. If it comes back positive and she progresses on immunotherapy, imatinib is sitting there ready as an informed second-line choice rather than a guess. If it's negative, we've lost nothing by not waiting.
Agreed: start pembrolizumab today rather than delaying for the KIT panel, which is sent in parallel and will inform second-line therapy specifically if she progresses.